10-Q: Akero Therapeutics Reports Q3 2024 Results, Progresses MASH Clinical Trials

Akero Therapeutics reports increased R&D spending in Q3 2024 as it advances its Phase 3 MASH program, while maintaining a strong cash position.

Summary

• Akero Therapeutics, a clinical-stage company, released its Q3 2024 financial results, showing a net loss of $72.7 million, compared to a net loss of $39.7 million in Q3 2023.
• The company's research and development expenses increased significantly to $72.2 million in Q3 2024, up from $38.6 million in Q3 2023, primarily due to increased clinical trial costs for its MASH program.
• General and administrative expenses also rose to $9.5 million in Q3 2024 from $8.0 million in Q3 2023.
• Akero reported a net loss of $182.0 million for the nine months ended September 30, 2024, compared to a net loss of $96.6 million for the same period in 2023.
• The company's cash, cash equivalents, and marketable securities totaled $787.1 million as of September 30, 2024.
• Akero believes its current cash position will fund operations into the second half of 2027.
• The company is progressing its Phase 3 SYNCHRONY program for MASH, with results from the SYMMETRY study expected in February 2025 and the SYNCHRONY Real-World study in 2026.
• The company has a term loan with Hercules Capital, with $35.0 million outstanding as of September 30, 2024, and the potential to borrow an additional $65.0 million.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the company has a strong cash position and is progressing its clinical trials, the increasing losses and reliance on a single product candidate raise concerns. The competitive landscape and regulatory uncertainties also contribute to a neutral sentiment.

Positives

• Akero has a strong cash position of $787.1 million, which is expected to fund operations into the second half of 2027.
• The company is making progress with its Phase 3 SYNCHRONY program for MASH, with key data readouts expected in the near future.
• The company has successfully manufactured API and a DP-device combination under GMP conditions for use in its Phase 3 SYNCHRONY program.
• The company has begun negotiating terms for commercial supply with its contract manufacturers.

Negatives

• Akero's net loss increased significantly in Q3 2024 to $72.7 million, compared to $39.7 million in Q3 2023.
• Research and development expenses have increased substantially, reflecting the high cost of clinical trials.
• The company has not generated any revenue since its inception and does not expect to generate any revenue from product sales in the near future.
• The company is heavily dependent on the success of EFX, its only product candidate.

Risks

• The company faces substantial competition in the MASH treatment space.
• Clinical trial delays or failures could significantly impact the company's ability to obtain regulatory approvals and commercialize its product candidates.
• Manufacturing complexities and potential issues with third-party manufacturers could disrupt the supply of product candidates.
• The company is dependent on the success of EFX, and failure to commercialize it would significantly harm the business.
• The company may be required to make significant payments under its license agreement with Amgen.
• The regulatory approval processes are lengthy, time-consuming, and inherently unpredictable.
• The company may be subject to product liability claims if its products exhibit harmful side effects after approval.
• The company may be required to raise additional capital, which may not be available on acceptable terms or at all.
• The company is subject to various healthcare laws and regulations, which, if violated, could expose it to criminal sanctions and civil penalties.
• The company is subject to a lawsuit alleging misstatements and omissions regarding the Phase 2b SYMMETRY study.

Future Outlook

Akero expects its current cash position to fund operations into the second half of 2027 and anticipates reporting key data readouts from its ongoing clinical trials in the near future.

Management Comments

• Management believes EFX has the potential to be an important medicine for treating MASH.
• Management expects that its existing cash, cash equivalents and shortand long-term marketable securities will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance date of these condensed consolidated financial statements.

Industry Context

The document highlights the competitive landscape in the MASH treatment space, with numerous companies pursuing similar therapies. Akero is positioning EFX as a potential best-in-class FGF21 analog, emphasizing its ability to address multiple stages of MASH pathogenesis.

Comparison to Industry Standards

• The document mentions several competitors in the MASH space, including large pharmaceutical companies like AstraZeneca, Boehringer Ingelheim, and Pfizer, as well as smaller biotech firms such as Madrigal Pharmaceuticals and Gilead Sciences.
• Madrigal Pharmaceuticals recently received FDA approval for Rezdiffra, a MASH treatment, which may impact patient enrollment in Akero's clinical trials.
• Akero's focus on a FGF21 analog differentiates it from some competitors, but it also faces competition from other companies developing similar therapies.
• The company's cash position of $787.1 million is relatively strong compared to other clinical-stage biotech companies, providing a runway into the second half of 2027.
• The increase in R&D expenses is consistent with the industry trend of high costs associated with late-stage clinical trials.

Legal Proceedings

• On April 26, 2024, a purported stockholder of the Company filed a lawsuit, captioned Klobus v. Akero Therapeutics, Inc., No. 3:24-cv-02534 (N.D. Cal.), in the U.S. District Court for the Northern District of California against the Company and three of its officers.
• The suit purports to be filed on behalf of a class of stockholders who purchased or otherwise acquired Company common stock between September 13, 2022 and October 9, 2023.
• The suit asserts claims under the Exchange Act for alleged misstatements and omissions regarding the Companys Phase 2b SYMMETRY study.
• The complaint seeks damages in an unspecified amount.
• The court appointed lead plaintiffs and lead counsel on August 2, 2024.
• Lead Plaintiffs filed an amended complaint on September 24, 2024.
• Defendants anticipated motion to dismiss is due on November 18, 2024.

Stakeholder Impact

• Shareholders face the risk of potential losses due to the company's increasing net losses and reliance on a single product candidate.
• Employees may be affected by potential changes in the company's operations or financial stability.
• Patients may benefit from the development of new treatments for MASH, but also face the risk of potential side effects.
• Suppliers and contract manufacturers may be affected by changes in the company's financial condition or development plans.
• Creditors, such as Hercules Capital, face the risk of potential default on the company's debt obligations.

Next Steps

• The company will continue to enroll patients in its Phase 3 SYNCHRONY program.
• The company expects to report Week 96 results from the Phase 2b SYMMETRY study in February 2025.
• The company expects to report results from the SYNCHRONY Real-World study in 2026.
• The company expects to report results for the 52-week primary histology endpoint of the SYNCHRONY Histology study in the first half of 2027.
• The company will continue to negotiate terms for commercial supply with its contract manufacturers.

Key Dates

Keywords

MASH, efruxifermin, EFX, clinical trials, Phase 3, SYNCHRONY, biotechnology, liver disease, fibrosis, regulatory approval